Everything below concerns hGH fragment. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-09-24. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
==== Camphor-alcohol treatment ==== Camphor treatment is similar to the alcohol-ether treatment but instead of a quick evaporation of the alcohol inside of the cells, the camphor alcohol slowly replaces cell walls with camphor which goes from a solid to a gas state over time, keeping walls of cells bulked. As a volatile solvent treatment option, the impact on the health and safety on the workplace must be considered.
== Diagnosis == Diabetes of any type is typically diagnosed by a blood test showing unusually high blood sugar. The World Health Organization defines diabetes as blood sugar levels at or above 7.0 mmol/L (126 mg/dL) after fasting for at least eight hours, or a glucose level at or above 11.1 mmol/L (200 mg/dL) two hours after an oral glucose tolerance test. The American Diabetes Association additionally recommends a diagnosis of diabetes for anyone with symptoms of hyperglycemia and blood sugar at any time at or above 11.1 mmol/L, or glycated hemoglobin (hemoglobin A1C) levels at or above 48 mmol/mol (6.5%). Once a diagnosis of diabetes is established, type 1 diabetes is distinguished from other types by a blood test for the presence of autoantibodies that target various components of the beta cell. The most commonly available tests detect antibodies against glutamic acid decarboxylase, the beta cell cytoplasm, or insulin, each of which is targeted by antibodies in around 80% of type 1 diabetics. Some healthcare providers also have access to tests for antibodies targeting the beta cell proteins IA-2 and ZnT8; these antibodies are present in around 58% and 80% of people with type 1 diabetes, respectively. Some also test for C-peptide, a byproduct of insulin synthesis. Very low C-peptide levels are suggestive of type 1 diabetes. The median age of type 1 diabetes diagnosis in the United States is 24 years of age.
The removal of the docks to Avonmouth, seven miles (11 km) downstream from the city centre, relieved congestion in the central zone of Bristol and allowed substantial redevelopment of the old central dock area (the Floating Harbour) in the late 20th century. The deep-water Royal Portbury Dock was developed opposite Avonmouth Docks in the 1970s and following privatisation of the Port of Bristol has become financially successful. At one time the continued existence of the old central docks was in jeopardy as it was seen merely as derelict industry rather than an asset to be developed for public use. Since the 1980s millions of pounds have been spent regenerating the harbourside. 1999 saw the redevelopment of the city centre and the construction of Pero's footbridge; which now links the At-Bristol science centre at Canon's Marsh, opened in 2000, with other Bristol tourist attractions. Private investors are also constructing studio apartment buildings. The regeneration of the Canon's Marsh area is expected to cost £240 million. Crest Nicholson were the lead developers constructing 450 new flats, homes and waterside offices, under the guidance of The Harbourside Sponsors' Group which is a partnership between the City Council, developers, businesses, and public funders.
After his daughter was born, Marrow enlisted in the United States Army in October 1977. Following basic training, Marrow was assigned to the 25th Infantry Division. During his time in the army Marrow was involved with a group of soldiers charged with the theft of a rug. While awaiting trial, he received a $2,500 bonus check and went absent without leave (AWOL), returning a month later, after the rug had been returned. Marrow received a non-judicial punishment as a consequence of his dereliction of duty. During his spell in the Army, Marrow became interested in hip-hop. He heard The Sugarhill Gang's newly released single "Rapper's Delight" (1979), which inspired him to perform his own raps over the instrumentals of this and other early hip-hop records. The music, however, did not fit his lyrics or form of delivery. When he was stationed in Hawaii (where prostitution was not a heavily prosecuted crime) as a squad leader at Schofield Barracks, Marrow met a pimp named Mac. Mac admired that Marrow could quote Iceberg Slim, and he taught Marrow how to be a pimp himself. Marrow was also able to purchase stereo equipment cheaply in Hawaii, including two Technics turntables, a mixer, and large speakers. Once equipped, he then began to learn turntablism and rapping. Marrow learned from his commanding officer that he could receive an early honorable discharge because he was a single father. Taking advantage of this, Marrow was discharged as a Private First Class (PFC - E3) in December 1979 after serving for two years and two months.
Sources: en.wikipedia.org
=== Former === Jeff Jones – lead vocals, bass (1968) John Rutsey – drums, percussion, backing vocals (1968–1974; died 2008), lyrics (1968–1973) Joe Perna – bass, lead and backing vocals (1969) Lindy Young – keyboards, backing and lead vocals, guitars, percussion, harmonica (1969) Bob Vopni – guitars, backing vocals (1969) Mitch Bossi – guitars, backing vocals (1971–1972) Neil Peart – drums, percussion, lyrics (1974–2015; died 2020)
It is assumed that the transection of white substance of the frontal lobes impairs their connection with the thalamus and eliminates the possibility of receiving from it stimuli which lead to irritation and, on the whole, derange mental functions. This explanation is mechanistic and goes back to the narrow localizationism characteristic of American psychiatrists, from where leucotomy was imported to us. The Soviet Union officially banned the procedure in 1950 on the initiative of Gilyarovsky. Doctors in the Soviet Union concluded that the procedure was "contrary to the principles of humanity" and "'through lobotomy' an insane person is changed into an idiot". By the 1970s, numerous countries had banned the procedure, as had several US states. In 1977 after the National Research Act created the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, the Commission investigated allegations that psychosurgery – including lobotomy techniques – were used to control minorities and restrain individual rights. Its published report did not recommend a ban on psychosurgery, but noted that the risks to patients from psychosurgery and its potential abuse required strong safeguards. Torsten Wiesel has called the award of the Nobel Prize to Moniz an "astounding [error] of judgment ... a terrible mistake", and there have been calls for the Nobel Foundation to rescind the award.
=== In ejaculation === The prostate secretes fluid, which becomes part of the semen. Its secretion forms up to 30% of the semen. Semen is the fluid emitted (ejaculated) through the male urethra during the sexual response. Sperm are emitted from the vas deferens into the male urethra via the ejaculatory duct, which lies within the prostate gland. Semen is moved into the urethra following contractions of the smooth muscle of the vas deferens and seminal vesicles, following stimulation, primarily of the glans penis. Stimulation sends nerve signals via the internal pudendal nerves to the upper lumbar spine; the nerve signals causing contraction act via the hypogastric nerves. After traveling into the urethra, the seminal fluid is ejaculated by contraction of the bulbocavernosus muscle. The secretions of the prostate include proteolytic enzymes, prostatic acid phosphatase, fibrinolysin, zinc, and prostate-specific antigen. Together with the secretions from the seminal vesicles, these form the major fluid part of semen. The prostate contains various metals, including zinc, and is known to be the primary source of most metals found in semen, which are released during ejaculation.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.